[Antiviral humanized and human monoclonal antibodies]
- PMID: 22171470
[Antiviral humanized and human monoclonal antibodies]
Abstract
The paper considers the characteristics of monoclonal antibodies, methods for their experimental preparation, problems of their production, and possibilities of their use for the emergency prevention of viral infections and for the treatment of chronic diseases caused by human immunodeficiency virus, hepatitis B and C viruses, and herpes viruses. The future of experimentally produced or clinically trialed monoclonal antibodies is mainly determined by commercial considerations. It is possible that simplification of industrial production technologies and a reduction in the cost of evidence-based methods for evaluation of clinical effectiveness will allow monoclonal antibodies to be extensively used for the prevention and treatment of viral infections.
Similar articles
-
Respiratory syncytial virus: concerns and control.Pediatr Rev. 2003 Sep;24(9):301-9. doi: 10.1542/pir.24-9-301. Pediatr Rev. 2003. PMID: 12949266 No abstract available.
-
Respiratory syncytial virus: different criteria for palivizumab use in different areas?South Med J. 2007 Jul;100(7):661-2. doi: 10.1097/SMJ.0b013e318070ca99. South Med J. 2007. PMID: 17639741 No abstract available.
-
Antibodies for the prevention and treatment of viral diseases.Antiviral Res. 2000 Aug;47(2):57-77. doi: 10.1016/s0166-3542(00)00111-x. Antiviral Res. 2000. PMID: 10996394 Review.
-
Prevention of respiratory syncytial virus infection with palivizumab.Monaldi Arch Chest Dis. 2000 Aug;55(4):333-8. Monaldi Arch Chest Dis. 2000. PMID: 11057088 Review.
-
[Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].Vestn Ross Akad Med Nauk. 2012;(12):30, 32-4. Vestn Ross Akad Med Nauk. 2012. PMID: 23530423 Clinical Trial. Russian.